AHA: Cardiac Troponin I IDs Low Risk of MI, Cardiac Death
In suspected ACS, high-sensitivity cardiac troponin I concentration <;5 ng/mL IDs those at low risk
MONDAY, Nov. 13, 2017 (HealthDay News) -- High-sensitivity cardiac troponin I concentration can identify individuals at low risk of myocardial infarction or cardiac death within 30 days among patients with suspected acute coronary syndrome, according to a review published online Nov. 11 in the Journal of the American Medical Association to coincide with the American Heart Association's Scientific Sessions, being held Nov. 11 to 15 in Anaheim, California.
Andrew R. Chapman, M.D., from the University of Edinburgh in Scotland, and colleagues conducted a systematic review to examine the performance of a cardiac troponin I threshold of 5 ng/L at presentation for risk stratification in patients with suspected acute coronary syndrome.
The primary outcome of myocardial infarction or cardiac death at 30 days occurred in 12.4 percent of the 22,457 patients included in the meta-analysis. The researchers found that 49 percent of patients had cardiac troponin I concentrations <5 ng/L at presentation; among these patients there were 60 missed index or 30-day events, resulting in a negative predictive value of 99.5 percent for the primary outcome. There were no and seven (0.1 percent) cardiac deaths at 30 days and one year, respectively, with a negative predictive value of 99.9 percent for cardiac death.
"Among patients with suspected acute coronary syndrome, a high-sensitivity cardiac troponin I concentration of less than 5 ng/L identified those at low risk of myocardial infarction or cardiac death within 30 days. Further research is needed to understand the clinical utility and cost-effectiveness of this approach to risk stratification," the authors write.
Several authors disclosed financial ties to the biopharmaceutical and medical device industries.